Date:	March 2	9, 2022				
Your Name:	Your Name:HENRIK VERDER					
Manuscript	Title:	BRONCHOPULMONARY DYSPLASIA WITH FOCUS ON EARLY PREDICTION AND TREATMENT.				
A SCOPING	REVIEW					
Manuscript	number	(if known):PM-21-98				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Neze	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
/	Support for attending meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options		The study was part of a public-private partnership
			between department of Pediatrics Holbaek Hospital,
			Region Zealand, Denmark and SIME Diagnostic Ltd
			(trading as SIME Clinical AI), a private company focused
			on developing preventative, data-driven medicine in
			neonatology.
			Henrik Verder hold part of a patent for spectroscopic
			analysis of biological samples and a patent for prediction
			of bronchopulmonary dysplasia and are option holder of
			SIME Diagnostics Ltd.
12	Receipt of equipment,	None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The study was part of a public-private partnership between department of Pediatrics Holbaek Hospital, Region Zealand, Denmark and SIME Diagnostic Ltd (trading as SIME Clinical AI), a private company focused on developing preventative, data-driven medicine in neonatology.

Henrik Verder hold part of a patent for spectroscopic analysis of biological samples and a patent for prediction of bronchopulmonary dysplasia and are option holder of SIME Diagnostics Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:29 March 2022				
Your Name:Zhan-Kui Li				
Manuscript Title: BRONCHOPULMONARY DYSPLASIA WITH FOCUS ON EARLY PREDICTION AND TREA	TMENT.			
A SCOPING REVIEW				
Manuscript number (if known):PM-21-98				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All success for the process		
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

Date:29 March 2022
Your Name:RAMANATHAN RANGASAMY
Manuscript Title: BRONCHOPULMONARY DYSPLASIA WITH FOCUS ON EARLY PREDICTION AND TREATMENT.
A SCOPING REVIEW
Manuscript number (if known):PM-21-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

Date:	29 Marc	ch 2022			
Your Name	Your Name:Howard Clark				
Manuscript	Title:	BRONCHOPULMONARY DYSPLASIA WITH FOCUS ON EARLY PREDICTION AND TREATMENT.			
A SCOPING	REVIEV	V			
Manuscript	numbe	r (if known):PM-21-98			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options		Howard Clark is a director of Trimonocor Ltd which is a
			company developing novel surfactant therapy.
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Howard Clark is a director of Trimonocor Ltd which is a company developing novel surfactant therapy.

Please place an "X" next to the following statement to indicate your agreement:

Date:29 March 2022	
Your Name: David Sweet	
Manuscript Title: BRONCHOPULMONARY DYSPLASIA WITH FOCI	JS ON EARLY PREDICTION AND TREATMENT.
A SCOPING REVIEW	
Manuscript number (if known):PM-21-98	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	None	
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	News	
6	Payment for expert	None	
	testimony		
7			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
4.0			
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
15	financial interests		
	manetal merests		

Please place an "X" next to the following statement to indicate your agreement:

Of Sweet.

Date:29 March 2022
Your Name:PETER SCHOUSBOE
Manuscript Title: BRONCHOPULMONARY DYSPLASIA WITH FOCUS ON EARLY PREDICTION AND TREATMENT.
A SCOPING REVIEW
Manuscript number (if known):PM-21-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options		The study was part of a public-private partnership
11			between department of Pediatrics Holbaek Hospital,
			Region Zealand, Denmark and SIME Diagnostic Ltd
			(trading as SIME Clinical AI), a private company focused
			on developing preventative, data-driven medicine in
			neonatology.
			Peter Schousboe hold part of a patent for prediction of
			bronchopulmonary dysplasia and are option holder of
			SIME Diagnostics Ltd.
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The study was part of a public-private partnership between department of Pediatrics Holbaek Hospital, Region Zealand, Denmark and SIME Diagnostic Ltd (trading as SIME Clinical AI), a private company focused on developing preventative, data-driven medicine in neonatology.

Peter Schousboe hold part of a patent for prediction of bronchopulmonary dysplasia and are option holder of SIME Diagnostics Ltd.

Please place an "X" next to the following statement to indicate your agreement: <u>\_\_</u>x\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:29 March 2022
Your Name:NIKOLAS SCOUTARIS
Manuscript Title: BRONCHOPULMONARY DYSPLASIA WITH FOCUS ON EARLY PREDICTION AND TREATMENT.
A SCOPING REVIEW
Manuscript number (if known):PM-21-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options		The study was part of a public-private partnership
11			between department of Pediatrics Holbaek Hospital,
			Region Zealand, Denmark and SIME Diagnostic Ltd
			(trading as SIME Clinical AI), a private company focused
			on developing preventative, data-driven medicine in
			neonatology.
			Nikolas Scoutaris hold part of a patent for prediction of
			bronchopulmonary dysplasia and are option holder of
			SIME Diagnostics Ltd.
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The study was part of a public-private partnership between department of Pediatrics Holbaek Hospital, Region Zealand, Denmark and SIME Diagnostic Ltd (trading as SIME Clinical AI), a private company focused on developing preventative, data-driven medicine in neonatology.

Nikolas Scoutaris hold part of a patent for prediction of bronchopulmonary dysplasia and are option holder of SIME Diagnostics Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:	29 Marcl	า 2022
Your Name	:POV	'L VERDER
Manuscript	: Title:	BRONCHOPULMONARY DYSPLASIA WITH FOCUS ON EARLY PREDICTION AND TREATMENT.
A SCOPING	<b>REVIEW</b>	
Manuscript	number	(if known):PM-21-98

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
-	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options		The study was part of a public-private partnership
			between department of Pediatrics Holbaek Hospital, Region Zealand, Denmark and SIME Diagnostic Ltd
			(trading as SIME Clinical AI), a private company focused on developing preventative, data-driven medicine in
			neonatology.
			Povl Verder hold part of a patent for prediction of
			bronchopulmonary dysplasia and are option holder of SIME Diagnostics Ltd. Povl Verder is CEO of SIME Ltd.
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

The study was part of a public-private partnership between department of Pediatrics Holbaek Hospital, Region Zealand, Denmark and SIME Diagnostic Ltd (trading as SIME Clinical AI), a private company focused on developing preventative, data-driven medicine in neonatology.

Povl Verder hold part of a patent for prediction of bronchopulmonary dysplasia and are option holder of SIME Diagnostics Ltd. Povl Verder is CEO of SIME Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:	Pate:29 March 2022						
Your Name	:	_Christian Heiring					
Manuscript	Title:	BRONCHOPULMONARY DYSPLASIA WITH FOCUS ON EARLY PREDICTION AND TREATMENT.					
A SCOPING REVIEW							
Manuscript	number	(if known):PM-21-98					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)					
	Time frame: Since the initial planning of the work							
1	All support for the present manuscript (e.g., funding,	None						
	provision of study materials, medical writing, article							
	processing charges, etc.)							
	No time limit for this item.							
	Time frame: past 36 months							
2	Grants or contracts from	None						
	any entity (if not indicated							
	in item #1 above).							
3	Royalties or licenses	None						
4	Consulting fees	None						

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
15	financial interests		

Please place an "X" next to the following statement to indicate your agreement: